Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience

Enzalutamide and abiraterone have been shown to improve progression-free survival (PFS) and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients. Moreover, some patients may not benefit from the inhibition of androgen receptor (AR) activity or, alternatively, may...

Descripción completa

Detalles Bibliográficos
Autores principales: Sepe, Pierangela, Verzoni, Elena, Miodini, Patrizia, Claps, Melanie, Ratta, Raffaele, Martinetti, Antonia, Mennitto, Roberta, Sottotetti, Elisa, Procopio, Giuseppe, Cappelletti, Vera, Daidone, Maria Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678845/
https://www.ncbi.nlm.nih.gov/pubmed/31337040
http://dx.doi.org/10.3390/cancers11070980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678845/
https://www.ncbi.nlm.nih.gov/pubmed/31337040
http://dx.doi.org/10.3390/cancers11070980

Ejemplares similares